| Name | BAY 41-2272 |
| Description | BAY 41-2272 is a direct and NO-independent soluble guanylate cyclase (sGC) stimulator. |
| In vitro | In vitro, BAY 41-2272 results in concentration dependent relaxation of human and rabbit cavernosum with EC50 of 489.1 nM and 406.3 nM, respectively. [3] |
| In vivo | In female spontaneously hypertensive rats, BAY 41-2272 (10 mg/kg, p.o.) shows antiplatelet effect, strongly decreases blood pressure and increases survival. [2] In C. albicans-infected mice, BAY 41-2272 (10 mg/kg, i.p.) markedly increases macrophage-dependent cell influx to the peritoneum in addition to macrophage functions, and reduces the death rate. [4] In db/db-/- type II diabetic and obese mice, BAY 41-2272 improves impaired corpus cavernosum (CC) relaxation. [5] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 36 mg/mL (99.89 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.77 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Guanylatecyclase | Guanylate cyclase | BAY 41-2272 | BAY 412272 | BAY 41 2272 |
| Inhibitors Related | LY83583 | Lificiguat | Sinitrodil | NPR-C activator 1 | Riociguat | Nelociguat | Nitroprusside disodium dihydrate | NS-2028 | Indusatumab | Methylene Blue | Methylene Blue trihydrate | Cinaciguat |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | NO PAINS Compound Library | Anti-Cardiovascular Disease Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | GPCR Compound Library | Anti-Cancer Compound Library | Human Metabolite Library | Anti-Hypertension Compound Library |